A pilot study of COVID-19 outcomes in people living with HIV in Tatarstan

Abstract

The coronavirus disease 2019 (COVID-19) pandemic remains a significant public health threat globally with significant socio-economic impacts. People living with human immunodeficiency virus (HIV) (PLWH) have a high risk of severe outcomes of COVID-19 due to immunosuppression. Clinical manifestation of COVID-19 in HIV patients largely remains unclear. We carried out a pilot study to investigate the clinical laboratory data and circulating cytokines in PLWH infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in Tatarstan, Russia. Serum samples were collected from three groups: PLWH with COVID-19 (PLWH/COVID-19), COVID-19-only, and uninfected controls. We found an increased risk of severe COVID-19 in PLWH/COVID-19 patients compared to COVID-19-only. Four fatal cases were in PLWH/COVID-19, while there was no fatality in COVID-19-only. Pro-inflammatory cytokines, such as IL-5, IL-6, IL-9, and IL-15, were elevated in PLWH/COVID-19 compered to COVID-19-only. These preliminary findings highlight the potential for more severe COVID-19 in PLWH/COVID-19 where pro-inflammatory cytokines could play pathogenic role.

Description

This article belongs to the Special Issue Molecular Mechanisms and Therapeutic Targeting of Inflammatory Complications. DATA AVAILABILITY STATEMENT : The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.

Keywords

Coronavirus disease (COVID-19), People living with HIV (PLHIV), Human immunodeficiency virus (HIV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Tatarstan, Russia, Immune response

Sustainable Development Goals

SDG-03: Good health and well-being

Citation

Andreeva, N., Moiseeva, S., Garipova, A. et al. 2026, 'A pilot study of COVID-19 outcomes in people living with HIV in Tatarstan', International Journal of Molecular Sciences, vol. 27, no. 1, art. 288, pp. 1-13, doi : 10.3390/ijms27010288.